Does the media favor MDGL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 29 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer MDGL or BIIB?

In the previous week, Biogen had 43 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 68 mentions for Biogen and 25 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Madrigal Pharmaceuticals' score of 0.84 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 36 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDGL or INCY?

In the previous week, Incyte had 24 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 49 mentions for Incyte and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat Incyte's score of 0.76 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Incyte 23 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDGL or UTHR?

In the previous week, United Therapeutics had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 27 mentions for United Therapeutics and 25 mentions for Madrigal Pharmaceuticals. United Therapeutics' average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.84 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 20 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to NBIX or MDGL?

In the previous week, Neurocrine Biosciences had 39 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 64 mentions for Neurocrine Biosciences and 25 mentions for Madrigal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.92 beat Madrigal Pharmaceuticals' score of 0.84 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 24 Very Positive mention(s) 3 Positive mention(s) 23 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Madrigal Pharmaceuticals (MDGL) Competitors

$476.23 +8.91 (+1.91%)

As of 10:26 AM Eastern

Compare

MDGL vs. ALNY, BIIB, INCY, UTHR, and NBIX

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? MarketBeat compares Madrigal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Madrigal Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%

In the previous week, Alnylam Pharmaceuticals had 29 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its share price is 201% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.62	-$288.28M	-$12.89	N/A
Alnylam Pharmaceuticals	$3.71B	7.86	$313.75M	$5.38	40.56

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals presently has a consensus price target of $688.20, indicating a potential upside of 42.72%. Alnylam Pharmaceuticals has a consensus price target of $404.57, indicating a potential upside of 85.38%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Biogen had 43 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 68 mentions for Biogen and 25 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Madrigal Pharmaceuticals' score of 0.84 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	36 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its share price is 201% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals currently has a consensus price target of $688.20, suggesting a potential upside of 42.72%. Biogen has a consensus price target of $223.36, suggesting a potential upside of 10.37%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has a net margin of 8.32% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Biogen's return on equity of 11.18% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.62	-$288.28M	-$12.89	N/A
Biogen	$9.89B	3.02	$1.29B	$5.65	35.82

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Incyte?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Incyte has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.62	-$288.28M	-$12.89	N/A
Incyte	$5.82B	4.21	$1.29B	$7.85	15.39

Madrigal Pharmaceuticals currently has a consensus target price of $688.20, suggesting a potential upside of 42.72%. Incyte has a consensus target price of $119.60, suggesting a potential downside of 0.98%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Incyte had 24 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 49 mentions for Incyte and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat Incyte's score of 0.76 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Incyte	23 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a beta of -1.01, indicating that its stock price is 201% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Incyte has a net margin of 27.71% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Incyte's return on equity of 29.93% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Incyte	27.71%	29.93%	22.88%

Summary

Incyte beats Madrigal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, United Therapeutics had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 27 mentions for United Therapeutics and 25 mentions for Madrigal Pharmaceuticals. United Therapeutics' average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.84 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	20 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

United Therapeutics has a net margin of 40.62% compared to Madrigal Pharmaceuticals' net margin of -25.32%. United Therapeutics' return on equity of 19.24% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
United Therapeutics	40.62%	19.24%	17.25%

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Madrigal Pharmaceuticals presently has a consensus price target of $688.20, suggesting a potential upside of 42.72%. United Therapeutics has a consensus price target of $648.33, suggesting a potential upside of 24.94%. Given Madrigal Pharmaceuticals' higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.62	-$288.28M	-$12.89	N/A
United Therapeutics	$3.18B	6.92	$1.33B	$27.09	19.16

Summary

United Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Neurocrine Biosciences had 39 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 64 mentions for Neurocrine Biosciences and 25 mentions for Madrigal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.92 beat Madrigal Pharmaceuticals' score of 0.84 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	24 Very Positive mention(s)	3 Positive mention(s)	23 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market.

Neurocrine Biosciences presently has a consensus target price of $201.05, suggesting a potential upside of 18.18%. Madrigal Pharmaceuticals has a consensus target price of $688.20, suggesting a potential upside of 42.72%. Given Madrigal Pharmaceuticals' higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.96
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

Neurocrine Biosciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.98	$478.60M	$6.82	24.94
Madrigal Pharmaceuticals	$958.40M	11.62	-$288.28M	-$12.89	N/A

Neurocrine Biosciences has a net margin of 20.91% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Neurocrine Biosciences' return on equity of 22.43% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Madrigal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.14B	$3.51B	$6.81B	$12.55B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-37.41	7.39	282.12	24.83
Price / Sales	11.62	1,209.27	573.08	78.59
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	18.17	16.98	11.02	6.15
Net Income	-$288.28M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-12.53%	-1.85%	0.47%	1.17%
1 Month Performance	-8.69%	-8.52%	-4.24%	-3.46%
1 Year Performance	59.58%	47.51%	62.63%	19.43%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	4.1419 of 5 stars	$482.20 +3.2%	$688.20 +42.7%	+54.7%	$11.14B	$958.40M	N/A	90	Earnings Report Analyst Forecast Gap Up
ALNY Alnylam Pharmaceuticals	4.6995 of 5 stars	$278.40 +2.4%	$452.13 +62.4%	-48.9%	$36.28B	$3.71B	76.07	2,770	Trending News Analyst Forecast
BIIB Biogen	3.9455 of 5 stars	$200.14 -1.0%	$220.57 +10.2%	+53.8%	$29.85B	$9.89B	21.47	7,500	Earnings Report Analyst Downgrade Gap Up
INCY Incyte	2.8956 of 5 stars	$118.87 +1.0%	$111.10 -6.5%	+58.1%	$23.51B	$5.36B	16.79	2,844	Earnings Report Analyst Downgrade Gap Up
UTHR United Therapeutics	4.7137 of 5 stars	$527.94 -0.1%	$648.33 +22.8%	+75.9%	$22.43B	$3.18B	19.49	1,400	Positive News Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Is MDGL or ALNY more profitable?

Does the media favor MDGL or ALNY?

Which has more volatility and risk, MDGL or ALNY?

Which has higher earnings & valuation, MDGL or ALNY?

Do institutionals & insiders hold more shares of MDGL or ALNY?

Do analysts prefer MDGL or ALNY?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Does the media prefer MDGL or BIIB?

Which has more risk & volatility, MDGL or BIIB?

Do institutionals and insiders hold more shares of MDGL or BIIB?

Do analysts prefer MDGL or BIIB?

Is MDGL or BIIB more profitable?

Which has better valuation & earnings, MDGL or BIIB?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Which has stronger earnings and valuation, MDGL or INCY?

Do analysts prefer MDGL or INCY?

Does the media prefer MDGL or INCY?

Which has more risk and volatility, MDGL or INCY?

Do insiders and institutionals hold more shares of MDGL or INCY?

Is MDGL or INCY more profitable?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Does the media prefer MDGL or UTHR?

Do institutionals & insiders hold more shares of MDGL or UTHR?

Is MDGL or UTHR more profitable?

Which has more volatility and risk, MDGL or UTHR?

Do analysts prefer MDGL or UTHR?

Which has better valuation and earnings, MDGL or UTHR?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Does the media refer more to NBIX or MDGL?

Which has more volatility & risk, NBIX or MDGL?

Do analysts prefer NBIX or MDGL?

Which has better earnings & valuation, NBIX or MDGL?

Is NBIX or MDGL more profitable?

Do institutionals and insiders hold more shares of NBIX or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools